ESTRO 2024 - Abstract Book

S1874

Clinical - Mixed sites, palliation

ESTRO 2024

There was no statistically significant difference between three and five fraction groups in local-control, overall survival, distant-control, or time to systemic therapy (Figure 2). The local-control rate at 2 years was 87.29% (CI 78 97%) for 3#SABR and 87.94% (CI 79-98%) for 5#iSABR. These outcomes were not significantly affected by the primary tumour site, time from delivery of primary treatment to SABR or number of sites treated. Minimum dose (converted to BED10) delivered to the GTV had a small association with local-control (HR 0.95, p=0.036). Other dose criteria were not significantly associated with outcomes. Treatment was well tolerated with no grade 3+ events (CTCAE v5) detected in either arm.